Skip to main content

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
Li, J; Armstrong, AJ
Published in: Clin Adv Hematol Oncol
May 2015

Duke Scholars

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

May 2015

Volume

13

Issue

5

Start / End Page

293 / 298

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Taxoids
  • Radium
  • Prostatic Neoplasms, Castration-Resistant
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Male
  • Humans
  • Docetaxel
  • Clinical Decision-Making
 

Citation

APA
Chicago
ICMJE
MLA
NLM

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

May 2015

Volume

13

Issue

5

Start / End Page

293 / 298

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Taxoids
  • Radium
  • Prostatic Neoplasms, Castration-Resistant
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Male
  • Humans
  • Docetaxel
  • Clinical Decision-Making